Tweets
#RNL2024 @philseo: I now give Tociliizumab for nearly all patients with GCA
GiACTA shows we weren't doing well enough w/steroid monotherapy
GiACTA shows dosing frequency does not make big diff in new diagnosis, but makes a diff in relapsing disease https://t.co/khJe0bwKXy
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
GCA pts on Toci mgmt
#RNL2024 @RheumNow
@philseo rec's increase interval to q4w before d/c TCZ
Limited evidence from this from study of 17 patients where weaned off TCZ. Hopes to capture pts with mild flares with tapering dose.
MAGICA trial will study abrupt d/c v wean dose
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Burnout or Retire
Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv. Is it time to worry about burnout and those who are leaving healthcare?
https://t.co/p8ek7A8HAk https://t.co/nH5fDywLic
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with either anti-CD4 or anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. https://t.co/CahyGfTn4g https://t.co/lfpdgEvGmx
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
ICYMI: Sex Disparities in PsA/SpA
https://t.co/55zwjR8mNR https://t.co/fhhekNpHVA
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
ILD Onset in MDA-5 Dermatomyositis
MDA5 antibody-positive DM is a rare, aggressive and progressive subtype of DM. Its' severity is dependent on the development of progressive ILD, manifesting as either RPILD and CILD.
https://t.co/08wAYj06DH https://t.co/TQWHGR27O9
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
World Congress on OP, OA & MSK Disorders
Bone and musculoskeletal disease researchers and physicians from around the world will meet today in London for the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
https://t.co/kzvWD4Rmki https://t.co/PJQREsJO9v
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Neuropsychiatric SLE - 2/3 Improved at 12 Months
The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data.
https://t.co/p0GEtkUTdt https://t.co/EZhjH6PxWQ
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
TNFi mAbs, JAKi, –IL-17 are protective against Anterior Uveitis (AU) in AxSpA. Metanalysis of 44 RCTs shows AU IR:
- TNF mAbs: 4.1
- etanercept 5.4
- IL-17i: 2.8
- JAKi: 1.5
- placebo: 10.8 https://t.co/sxqCXkD0up https://t.co/XWXUPmCtZr
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Of 375 #Gout pts D/C pegloticase after a median of 8 infusions (taken 112days (max 1,240d). Only 73% had SUA < 6 during pegloticase. After D/C 84% went on ULT (63% allopurinol; 34% febuxostat; after mean 92d); after ≥ 30 days), 51% achieved SUA < 6 https://t.co/unkvt1whrs https://t.co/DgVpBgKXcm
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Mental health in 1150 adolescents & young adults w/ juvenile idiopathic arthritis (age 15.6 yrs; Dz duration 7.2 yrs, 43% oligo-, 26% polyarthritis): 30% reported suicidal thoughts, 19% mod-severe depressive/anxious Sxs (moreso in Females OR 2.33) https://t.co/THW1IMqZpa https://t.co/IU2Kr3efYj
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
ICYMI: Top 5 Clinical Pearls in RA Management
https://t.co/zWRXzHTtIo https://t.co/rbitB9oWQG
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
